Drugs / ANZURSTOBART
ANZURSTOBART
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05168202 | Jan 2022 → Jul 2024 | acute myeloid leukemia, myelodysplastic syndrome | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 1 | NCT03783403 | Mar 2019 → Aug 2024 | neoplasm | Celgene Corporation | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ANZURSTOBART | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095321 ↗ |
| Known as | BMS-986351 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095321 ↗ |
| Known as | CC-95251 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03783403 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5095321 ↗ |